BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 22315973)

  • 1. WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicity.
    Antenor-Dorsey JA; O'Malley KL
    Mol Neurodegener; 2012 Feb; 7():5. PubMed ID: 22315973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAD(+) and axon degeneration revisited: Nmnat1 cannot substitute for Wld(S) to delay Wallerian degeneration.
    Conforti L; Fang G; Beirowski B; Wang MS; Sorci L; Asress S; Adalbert R; Silva A; Bridge K; Huang XP; Magni G; Glass JD; Coleman MP
    Cell Death Differ; 2007 Jan; 14(1):116-27. PubMed ID: 16645633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of vincristine-induced neuropathy by WldS expression and the independence of the activity of Nmnat1.
    Watanabe M; Tsukiyama T; Hatakeyama S
    Neurosci Lett; 2007 Jan; 411(3):228-32. PubMed ID: 17113230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting NMNAT1 to axons and synapses transforms its neuroprotective potency in vivo.
    Babetto E; Beirowski B; Janeckova L; Brown R; Gilley J; Thomson D; Ribchester RR; Coleman MP
    J Neurosci; 2010 Oct; 30(40):13291-304. PubMed ID: 20926655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A local mechanism mediates NAD-dependent protection of axon degeneration.
    Wang J; Zhai Q; Chen Y; Lin E; Gu W; McBurney MW; He Z
    J Cell Biol; 2005 Aug; 170(3):349-55. PubMed ID: 16043516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The WldS protein protects against axonal degeneration: a model of gene therapy for peripheral neuropathy.
    Wang MS; Fang G; Culver DG; Davis AA; Rich MM; Glass JD
    Ann Neurol; 2001 Dec; 50(6):773-9. PubMed ID: 11761475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration.
    Yahata N; Yuasa S; Araki T
    J Neurosci; 2009 May; 29(19):6276-84. PubMed ID: 19439605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration.
    Meyer zu Horste G; Miesbach TA; Muller JI; Fledrich R; Stassart RM; Kieseier BC; Coleman MP; Sereda MW
    Neurobiol Dis; 2011 Apr; 42(1):1-8. PubMed ID: 21168501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracking in the Wlds--the hunting of the SIRT and the luring of the Draper.
    Fainzilber M; Twiss JL
    Neuron; 2006 Jun; 50(6):819-21. PubMed ID: 16772165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration.
    Araki T; Sasaki Y; Milbrandt J
    Science; 2004 Aug; 305(5686):1010-3. PubMed ID: 15310905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local axonal protection by WldS as revealed by conditional regulation of protein stability.
    Wang JT; Medress ZA; Vargas ME; Barres BA
    Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10093-100. PubMed ID: 26209654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide.
    Sasaki Y; Vohra BP; Lund FE; Milbrandt J
    J Neurosci; 2009 Apr; 29(17):5525-35. PubMed ID: 19403820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified cell cycle status in a mouse model of altered neuronal vulnerability (slow Wallerian degeneration; Wlds).
    Wishart TM; Pemberton HN; James SR; McCabe CJ; Gillingwater TH
    Genome Biol; 2008; 9(6):R101. PubMed ID: 18570652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing expression of NAD+ synthesizing enzyme NMNAT1 does not affect the rate of Wallerian degeneration.
    Conforti L; Janeckova L; Wagner D; Mazzola F; Cialabrini L; Di Stefano M; Orsomando G; Magni G; Bendotti C; Smyth N; Coleman M
    FEBS J; 2011 Aug; 278(15):2666-79. PubMed ID: 21615689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene.
    Mack TG; Reiner M; Beirowski B; Mi W; Emanuelli M; Wagner D; Thomson D; Gillingwater T; Court F; Conforti L; Fernando FS; Tarlton A; Andressen C; Addicks K; Magni G; Ribchester RR; Perry VH; Coleman MP
    Nat Neurosci; 2001 Dec; 4(12):1199-206. PubMed ID: 11770485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WldS can delay Wallerian degeneration in mice when interaction with valosin-containing protein is weakened.
    Beirowski B; Morreale G; Conforti L; Mazzola F; Di Stefano M; Wilbrey A; Babetto E; Janeckova L; Magni G; Coleman MP
    Neuroscience; 2010 Mar; 166(1):201-11. PubMed ID: 20018231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nmnat2 delays axon degeneration in superior cervical ganglia dependent on its NAD synthesis activity.
    Yan T; Feng Y; Zheng J; Ge X; Zhang Y; Wu D; Zhao J; Zhai Q
    Neurochem Int; 2010 Jan; 56(1):101-6. PubMed ID: 19778564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axonal involvement in the Wlds neuroprotective effect: analysis of pure motoneurons in a mouse model protected from motor neuron disease at a pre-symptomatic age.
    Simonin Y; Perrin FE; Kato AC
    J Neurochem; 2007 Apr; 101(2):530-42. PubMed ID: 17402973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axon degeneration: where the Wlds things are.
    Wang JT; Barres BA
    Curr Biol; 2012 Apr; 22(7):R221-3. PubMed ID: 22497934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wld S requires Nmnat1 enzymatic activity and N16-VCP interactions to suppress Wallerian degeneration.
    Avery MA; Sheehan AE; Kerr KS; Wang J; Freeman MR
    J Cell Biol; 2009 Feb; 184(4):501-13. PubMed ID: 19237597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.